Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HSPG2 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
HSPG2 siRNA is a small interfering RNA (siRNA) designed to target and silence the expression of heparan sulfate proteoglycan 2 (HSPG2), also known as perlecan. HSPG2 is a major basement membrane proteoglycan that plays critical roles in cell adhesion, tissue remodeling, and viral entry. In preclinical research, silencing HSPG2 with siRNA has been shown to inhibit hepatitis B virus (HBV) entry and replication in hepatocytes by downregulating the sodium taurocholate co-transporting polypeptide (NTCP) via the c-MET signaling pathway. Additionally, HSPG2 siRNA has been investigated in oncology and fibrosis models to study the role of perlecan in tumor progression, chemoresistance, and tissue fibrogenesis.
- Other names
- perlecan siRNA
02
Targets
HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))
Beyond the preview
Go deeper on HSPG2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HSPG2 siRNA.